194 results on '"Yang C"'
Search Results
2. MA10.08 The Disparate Burden of COVID-19 Lung Cancer Patients During Periods of High Transmission of SARS-CoV-2
3. EP12.02-07 The Effectiveness of Lorlatinib for Previously Treated ROS1-rearranged NSCLC: Real world Experience in Taiwan
4. MA02.08 Pack-Year Smoking History Is An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility
5. P1.02-01 HRA00129-C004, a Novel c-Met ADC with Promising Preclinical Anti-tumor Activity and Expanded Therapeutic Window
6. 12MO Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase III POSEIDON study
7. EP.02F.04 Development and Validation of an ADRB2-based Prognostic Model for Non-Small Cell Lung Cancer.
8. P1.03A.02 FBXO32 Promotes EMT and Regulates the Cell Cycle by Targeting PTEN for Proteasomal-Dependent Degradation in LUAD.
9. MA03.10 Association of Surgical Margin Distance, Locoregional Recurrence, and Survival Among Patients Undergoing Sublobar Resection in CALGB140503.
10. OA17.05 A Randomized Controlled Trial of a Digital Lung Health Intervention to Facilitate Smoking Cessation and Lung Cancer Screening.
11. EP14.05-003 Recent Stage Shifts and Changes in the Treatment of Stage I Small Cell Lung Cancer in the United States
12. OA02.04 Multimodal Management of T4 N2 Non-small-cell Lung Cancer with Additional Ipsilateral Pulmonary Nodules
13. EP08.02-127 Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study
14. MA04.09 The Incidence and Predictors of Unsuspected Brain Metastases in Patients with Stage IA NSCLC
15. MA02.07 Aurora A Kinase Inhibition with VIC-1911Potentiates KRASG12C Inhibitor and Overcomes Resistance to Sotorasib in Lung Cancer
16. OA05.03 Incidence, Timing, and Survival of Second Primary Lung Cancer in Patients in the National Lung Screening Trial
17. EP08.02-078 Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES)
18. OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC
19. MA04.05 T3 Defining Features Influence Long Term Survival after Resection of T3N0M0 NSCLC
20. OA05.06 Early Diagnosis of Lung Cancer Among Younger vs. Older Adults: Widening Disparities in the Era of Lung Cancer Screening
21. EP08.01-027 Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON
22. EP.13B.11 Clinical Outcomes of Continuous Immunotherapy Beyond Progression in Patients with Extensive-Stage Small Cell Lung Cancer
23. EP.07D.06 Characteristics of and Long-Term Outcomes of Non-Small-Cell Lung Cancer Diagnosed Among Young Adults in the United States
24. EP.02B.01 PIK3C2A Potentiates Angiogenesis of Non-Small Cell Lung Cancer by Regulating ADRB2/VEGFA Signaling Pathway
25. P3.13C.08 Optimal Treatment Strategies for Older Adults with Clinical Stage IA Small Cell Lung Cancer
26. MA18.08 Risk and Timing of Second Primary Lung Cancer Among Young Women with a History of Breast Cancer in the United States
27. MA04.04 Treatment Patterns and Survival of Screen-Detected Lung Cancer in the Real World Versus the National Lung Screening Trial
28. P4.07G.01 Incidence of and Outcomes of Second Primary Lung Cancer after Resection for Screen-Detected Lung Cancer
29. MA02.06 Phase 1b Study of Pelcitoclax (APG-1252) in Combination With Osimertinib in Patients With EGFR TKI-Resistant NSCLC
30. MA01.01 The Role of Surgery for M1a Non-Small-Cell Lung Cancer with Contralateral Lung Involvement
31. P06.03 The Role of Surgery for Stage 0 Adenocarcinoma in Situ of the Lung: A U.S. National Analysis
32. PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
33. OA20.04 Survival of Patients with Persistent N1 or N2 Disease After Induction Therapy for Stage IIIA-N2 Non-Small-Cell Lung Cancer
34. P86.15 Osimertinib Real-World Experience in EGFR T790M Positive Locally Advanced or Metastatic NSCLC in Taiwan
35. MA03.11 Cognitive Bias in Lung Cancer Surgery: The Left Digit Effect
36. P06.04 Single-Stage Bilateral Pulmonary Resections by Uniportal Video-Assisted Thoracic Surgery for Multiple Small Nodules
37. P21.12 An Observational Study of Treatment Outcome in Stage III Lung Cancer Patients in Taiwan: KINDLE study
38. MA02.03 Robot-Assisted Endoscopic Airway Reconstruction Using the Newly Developed Chinese Uniportal Robotic Surgical System
39. P46.07 An Extended Targeted RNA Sequencing for Fusion Detection with Oncomine Comprehensive Assay Plus
40. 28P Generation and validation of a predictive model using pretreatment clinical factors for estimating survival and T790M mutation in EGFR-mutated non-small cell lung cancer in Taiwan
41. OA03.09 Overall Survival in Patients with EGFRM+ NSCLC Receiving Sequential Afatinib and Osimertinib: an Update of the Giotag Study
42. PD2.05 Overall Survival in Pts with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: Updated Analysis of the GioTag Study
43. P1.14-62 Afatinib in EGFR TKI-Naïve Patients with EGFR Mutation-Positive NSCLC: Combined Analysis of Two Single-Arm Phase IIIb Studies
44. OA02.03 The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI
45. P2.01-99 A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naïve Patients with EGFR Mutation-Positive NSCLC: Final Analysis
46. P1.01-92 Underlying Mechanisms That Potentially Affect Prognosis to EGFR-TKI in EGFR-Positive Patients with Non-Small Cell Lung Cancer
47. P1.01-118 Overall Survival in Pts with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: Updated Analysis of the GioTag Study
48. P2.01-39 Serial Plasma ctDNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in T790M+ NSCLC
49. P1.01-50 Impact of Concomitant HER2 Alterations in Mediating Clinical Outcomes of EGFR-Mutant Patients to Different Generation of EGFR-TKIs
50. OA03 Afatinib Followed by Osimertinib in Real-World Patients with EGFR Mutation-Positive Advanced NSCLC: The Giotag Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.